No data to show
XTSE
CRDL
Market cap113mUSD
Jul 09, Last price
1.88CAD
1D
-1.05%
1Q
51.61%
IPO
-59.57%
Name
Cardiol Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
33.20%
Rev. gr., 5y
%
Revenues
0k
Net income
-28m
L-9.06%
CFO
-25m
Earnings
Aug 11, 2025
Profile
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 30,034 | 41,556 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (30,034) | (41,556) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (10,241) | |||||||
Tax Rate | ||||||||
NOPAT | (30,034) | (31,315) | ||||||
Net income | (28,128) -9.06% | (30,931) -2.24% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 21,356 | |||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 33 | 16 | 50 | |||||
Long-term debt | 284 | 333 | 95 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (30,263) | (34,583) | (59,324) | |||||
| Cash flow | ||||||||
Cash from operating activities | (25,061) | (27,220) | ||||||
CAPEX | (21) | (75) | ||||||
Cash from investing activities | (21) | (75) | ||||||
Cash from financing activities | 18,840 | (54) | ||||||
FCF | 141 | (30,075) | (31,254) | |||||
| Balance | ||||||||
Cash | 30,580 | 34,932 | 59,470 | |||||
Long term investments | ||||||||
Excess cash | 30,580 | 34,932 | 59,470 | |||||
Stockholders' equity | 81 | 9,461 | 36,615 | |||||
Invested Capital | 24,806 | 18,960 | 15,660 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 64,463 | 62,506 | ||||||
Price | 1.85 68.18% | 1.10 59.42% | 0.69 -70.39% | |||||
Market cap | 70,909 64.41% | 43,129 -57.17% | ||||||
EV | 36,326 | (16,195) | ||||||
EBITDA | 373 | (30,034) | (41,336) | |||||
EV/EBITDA | 0.39 | |||||||
Interest | ||||||||
Interest/NOPBT | ||||||||